Centessa Pharmaceuticals plc American Depositary Shares

Centessa Pharmaceuticals plc a clinical-stage pharmaceutical company discovers develops and delivers medicines to patients. Its pipeline products include SerpinPC an activated protein C inhibitor which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750 an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101 a PD-L1xCD47 LockBody which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292 a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy including TAK-861. In addition its products pipeline comprises CBS001 a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004 a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases as well as earlier-stage preclinical assets including ORX750 an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham the United Kingdom.